An Austin pharmacy is recalling three lots of compounded glutathione injection after its own testing found elevated bacterial endotoxin levels, and the company says patients have already reported reactions.
Victory Medical Center Pharmacy announced the voluntary recall of Compounded Glutathione 200 mg/mL Multi-Dose Vials on August 5, and the FDA published the company announcement the same day. The recall extends to the patient level, meaning the pharmacy is contacting individual patients rather than only clinics and distributors.
This is not a precautionary pull with no known harm attached. The company states that it has received reports of adverse events including fever, chills, severe headache, nausea, vomiting, tachycardia, changes in blood pressure, body aches, and injection site reactions. Those are the classic signs of an endotoxin reaction, and they can begin within minutes of an infusion.
Three Lots, One Expiration Date, and a Patient Level Recall
The recalled product is sold under the VMC brand as Compounded Glutathione 200 mg/mL in multi-dose vials. Three lot numbers are affected: 1980571, 1981940, and 1984345. All carry an expiration date of August 27, 2026.
The announcement is titled as a nationwide recall, but the company states the product was distributed to consumers in Texas, Florida, and New York. Anyone who has recently received a glutathione injection should still check the label against these lot numbers.
Victory Medical Center Pharmacy says it is notifying prescribers and patients by telephone and mail and is arranging retrieval and proper disposition of the recalled vials. Patients and prescribers will receive a full refund for recalled product if they have not already been reimbursed. The pharmacy can be reached at (512) 279-0985.
Endotoxin Reactions Begin Fast and Can Look Like Sudden Illness
Bacterial endotoxin is not a live infection. It is a component of the outer membrane of gram-negative bacteria, and it can remain present even after sterilization kills the organisms themselves. Injected directly into the bloodstream, it triggers a rapid immune response that can be severe.
The company's published risk statement is direct. It says there is a reasonable probability that injectable products with elevated endotoxin levels could cause significant medical events including fevers, low blood pressure, inflammatory reactions, anaphylactic shock, and death.
That language is the standard framing for a serious pharmaceutical recall, and it describes potential outcomes rather than confirmed ones in this case. The confirmed picture so far is the list of reported reactions above. The announcement discloses no deaths and no hospitalizations.
The practical distinction for a patient is timing. An endotoxin reaction typically appears during or within minutes to a few hours of an infusion, not days later.
Anyone who experienced symptoms after a glutathione injection should contact their prescribing physician. Severe shortness of breath, chest pain, fainting, a rapid drop in blood pressure, swelling of the face or throat, or a high fever with confusion require emergency evaluation rather than a phone call. This article is general information and is not a diagnosis.
A Familiar Problem in Compounded Glutathione
Compounded glutathione at this exact concentration has produced this exact problem before.
In February 2019, FDA warned compounders not to use glutathione powder distributed by Letco Medical of Decatur, Alabama, to compound sterile injectable drugs, citing potential endotoxins. The agency said Letco had supplied that powder to about 100 compounders in 30 states.
The trigger was a report FDA received on January 14, 2019, concerning seven patients at an outpatient clinic who received intravenous L-glutathione 200 mg/mL. Within minutes of the infusion, the patients experienced symptoms of varying degrees, including nausea, vomiting, lightheadedness, chills, body aches, and sneezing. One patient developed low blood pressure and difficulty breathing and was transferred to a hospital.
In a follow-up compounding alert, FDA said its own laboratory testing found excessive bacterial endotoxin in the powder, with some results as high as five times the appropriate limit for the dose patients received. The agency also noted the powder had been labeled with a dietary supplement caution and should not have been used to compound sterile injectable drugs.
The current recall is a separate event involving a different firm, and the announcement does not identify an ingredient source. But the pattern gives patients a useful question to ask: where did the raw material come from, and was the finished product tested before release?
It is also worth stating plainly what glutathione injection is and is not. FDA has not approved any injectable glutathione product. Compounded drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness, or quality. Injectable glutathione is widely marketed through wellness clinics and medical spas for skin lightening, antioxidant benefit, and general wellness, and none of those uses rests on FDA-approved labeling. Consumers weighing an IV drip should factor that regulatory status into the decision alongside price.
Steps for Patients, Prescribers and Clinics Holding Inventory
The pharmacy's instructions are specific. Patients with product from an affected lot should stop using it immediately and quarantine any recalled vials rather than discarding them. They should contact Victory Medical Center Pharmacy to arrange retrieval and proper disposition. Anyone who has experienced symptoms that may relate to the product should contact their prescribing physician.
Because these are multi-dose vials, a single container may have been used across several patients, which is part of why the recall extends to the patient level. Clinics and prescribers holding inventory should check lot numbers against the three listed and stop dispensing.
Reactions or quality problems can be reported to FDA's MedWatch program online, by mail or by fax, or by calling 1-800-332-1088 to request a form. Reporting matters here because the current adverse event picture comes from the company, and independent reports are what allow FDA to judge whether the problem is broader than three lots.
What remains unknown is the source of the endotoxin, whether additional lots will be added, whether any patient required hospitalization, and whether FDA will classify the recall or take further action. MedicalDaily will monitor FDA's enforcement report listings for a classification and any expansion.
Frequently Asked Questions
Which lots are affected? Lot numbers 1980571, 1981940 and 1984345 of VMC Compounded Glutathione 200 mg/mL Multi-Dose Vials, all expiring August 27, 2026.
Where was the product distributed? The company says it went to consumers in Texas, Florida, and New York, though the recall is announced as nationwide.
Have people been hurt? The company reports adverse events including fever, chills, severe headache, nausea, vomiting, tachycardia, blood pressure changes, body aches and injection site reactions. No deaths or hospitalizations are disclosed.
What is bacterial endotoxin? A component of the outer membrane of gram-negative bacteria that can remain after sterilization and provoke a rapid, sometimes severe immune reaction when injected.
How soon would a reaction appear? Typically during or within minutes to a few hours of the injection, not days afterward.
Is injectable glutathione FDA-approved? No. FDA has not approved any injectable glutathione product, and compounded drugs do not undergo FDA premarket review.
What should I do with a recalled vial? Stop using it, quarantine it rather than throwing it away, and call the pharmacy at (512) 279-0985 to arrange retrieval and a refund.
